<DOC>
	<DOCNO>NCT02883712</DOCNO>
	<brief_summary>Pharmacoresistant epilepsy remain around 30 % despite development 25 anti epileptic drug . Of course , explain pharmacoresistant epileptic brain disease , exemplify genetic disease . However , lack specific guideline choice anti epileptic drug ( apart generalize partial epilepsy ) large number drug different sometimes complex metabolism challenge neurologist . Among 30 % pharmacoresistant epilepsy , part relate pharmacokinetic drawback could overcome rigorous approach ( i.e . dosage pharmacogenetics tool ) . Moreover , new anti epileptic drug metabolism unrelated cytochrome P450 le generalise adverse event . However , metabolism could complexe ( i.e . le known Uridine 5'-diphospho-glucuronyltransferase ( UGT ) pathway ) bring insidious neurological adverse event ( i.e . depression , anxiety exacerbation , cognitive disorder worsen ) could largely impede observance quality life even number seizure reduce . The goal determine predictive modulating factor pharmacoresistance global analysis ( i.e . whatever anti epileptic drug ) specific analysis ( drug drug ) cohort 1000 patient .</brief_summary>
	<brief_title>Study Predictors Response Anti Epilepsy Epilepsy</brief_title>
	<detailed_description>The goal determine predictive modulating factor pharmacoresistance global analysis ( i.e . whatever anti epileptic drug ) specific analysis ( drug drug specific metabolism pathway ) cohort 1000 patient . The response antiepileptic drug modification analyse 3 month modification , analysis number seizure , quality life , Clinical Global Impression , adverse event , systematic dosage molecule ( residual concentration take ) pharmacogenetic analysis main metabolism pathway main pharmacodynamic target .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Epileptic patient require treatment adaptation patient unable give reliable information without caregiver pregnancy Severe comorbidity , would impede interpretation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>epilepsy</keyword>
	<keyword>pharmacoresistant</keyword>
	<keyword>antiepileptic drug</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>pharmacogenetic</keyword>
</DOC>